Last updated on January 2020

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004


Brief description of study

The purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended treatment duration with AP-CD/LD after they have successfully completed the Phase 3 core study IN 11 004 ('core study', a phase III, multicenter, randomized, double-blind, double-dummy, active-controlled Phase 3 study to assess the safety and efficacy of AP CD/LD versus IR CD/LD in fluctuating PD patients).

Detailed Study Description

This will be a multi-center, global, open-label study in adult suffering from fluctuating Parkinson's disease subjects who have successfully completed the core study IN 11 004.

After signing informed consent and meeting inclusion/exclusion criteria, eligible subjects will be enrolled into a 12-month open-label extension and receive the AP-CD/LD as needed.

Efficacy and safety will be assessed throughout the study period.

Clinical Study Identifier: NCT02615873

Find a site near you

Start Over

SC3 Research

Pasadena, CA United States
  Connect »

University of Southern California

Los Angeles, CA United States
  Connect »

David L. Kreitzman, MD., PC

Commack, NY United States
  Connect »

Sentara Neurology Specialists

Virginia Beach, VA United States
  Connect »

Bioclinica Research

Orlando, FL United States
  Connect »

The University of Kansas Hospital

Kansas City, KS United States
  Connect »

Michigan State University

East Lansing, MI United States
  Connect »

University of Toledo

Toledo, OH United States
  Connect »

Quest Research Institute

Farmington Hills, MI United States
  Connect »

Charlottesville Medical Research

Charlottesville, VA United States
  Connect »

University of Cincinnati

Cincinnati, OH United States
  Connect »

Hartford HealthCare

Vernon, CT United States
  Connect »

Henry Ford Hospital

West Bloomfield, MI United States
  Connect »

SC3 Research

Reseda, CA United States
  Connect »

Konz lium

Dubnica nad Váhom, Slovakia
  Connect »